Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe/Daiichi Sankyo) Overview and Profile 2019 - ResearchAndMarkets.com

DUBLIN--()--The "Invokana" report has been added to ResearchAndMarkets.com's offering.

Invokana (canagliflozin; Johnson & Johnson/Mitsubishi Tanabe/Daiichi Sankyo) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism.

They prevent filtered glucose from being reabsorbed in the kidney rather than actively facilitating glucose filtration and excretion. Due to this distinct mechanism of action, when SGLT-2 inhibitors are used as monotherapy they do not lower glucose to unsafe levels and thus avoid the risk of hypoglycemia.

Key Topics Covered:

OVERVIEW

  • Drug Overview
  • Product Profiles
  • Invokana : Diabetic nephropathy
  • Invokana : Diabetes type 2

LIST OF FIGURES

  • The authors drug assessment summary of Invokana for diabetic nephropathy
  • The authors drug assessment summary of Invokana for diabetic nephropathy
  • Invokana sales for diabetic nephropathy across the US, Japan, and five major EU markets, by country, 2017-26
  • Invokana for type 2 diabetes - SWOT analysis
  • The authors drug assessment of Invokana
  • The authors drug assessment scorecard for Invokana compared to Januvia
  • Invokana sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25
  • Invokamet sales for type 2 diabetes across the US, Japan, and five major EU markets, by country, 2016-25

LIST OF TABLES

  • Invokana drug profile
  • Invokana Phase III trial in diabetic nephropathy
  • Invokana for diabetic nephropathy - SWOT analysis
  • Invokana drug profile
  • Overview of pivotal trial data for Invokana in diabetes
  • Key endpoint data from the CANVAS trial program
  • Invokana sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Invokamet sales for type 2 diabetes across the US, Japan, and five major EU markets, by country ($m), 2016-25

For more information about this report visit https://www.researchandmarkets.com/r/nx5yf9

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs, Diabetes Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs, Diabetes Drugs